Axonics® announces comprehensive launch of the axonics f15™ recharge-free sacral neuromodulation system

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the comprehensive launch of the axonics f15 across the united states. the newly developed, long-lived, fully recharge-free sacral neuromodulation (snm) system received fda approval in march. “the axonics recharge-free system is a welcome advancement for patients suffering from
AXNX Ratings Summary
AXNX Quant Ranking